Unituxin

(Dinutuximab)

Unituxin

Drug updated on 11/10/2023

Dosage FormInjection (intravenous; 17.5 mg/5 mL)
Drug ClassGD2-binding monoclonal antibodies
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.